| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1370627 | Bioorganic & Medicinal Chemistry Letters | 2011 | 5 Pages |
Abstract
Starting with the molecular scaffold of the DA2/β2 dual agonist sibenadet (Viozan™), a number of molecular changes were incorporated, which were designed to increase the potency and selectivity of the target molecule, and improve its pharmacokinetics. Through this process a novel, high potency, full β2-agonist with high selectivity and long duration capable of being dosed once daily has been discovered.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Stephen Connolly, Lilian Alcaraz, Andrew Bailey, Elaine Cadogan, Jadeen Christie, Anthony R. Cook, Adrian J. Fisher, Stephen Hill, Alexander Humphries, Anthony H. Ingall, Zoe Kane, Stuart Paine, Garry Pairaudeau, Michael J. Stocks, Alan Young,